Comparative Pharmacology
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus PULMOLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus PULMOLITE.
FLUDEOXYGLUCOSE F18 vs PULMOLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludeoxyglucose F18 is a glucose analog that is taken up by cells via glucose transporters (GLUT), particularly GLUT-1. It is phosphorylated to FDG-6-phosphate by hexokinase, which cannot be further metabolized, leading to intracellular accumulation proportional to glucose metabolism. It emits positrons detected by PET imaging.
PULMOLITE is a leukotriene receptor antagonist (LTRA) that selectively and competitively inhibits the cysteinyl leukotriene (CysLT1) receptor in the human airway, thereby reducing bronchoconstriction, mucus secretion, and eosinophilic infiltration.
5-10 mCi (185-370 MBq) intravenous injection, single dose for PET imaging.
Adults: 200 mg intravenously every 12 hours over 30 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 110 minutes (range 100–120 minutes). This reflects clearance of unmetabolized FDG from plasma and is clinically relevant for imaging timing, as optimal image acquisition occurs 30–60 minutes post-injection to allow for target-to-background ratio maximization.
Terminal elimination half-life: 12 hours (range 10–14 h) in adults with normal renal function (CrCl >90 mL/min); prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
Primarily renal; approximately 90% of injected activity is excreted unchanged in urine within the first 2 hours post-injection. Less than 5% is eliminated via feces.
Primarily renal (80%) as unchanged drug; 15% fecal via biliary excretion; 5% metabolized.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical